They produce hematopoietic stem cells from iPS cells in humans.

Prof. Nakauchi of Tokyo Institute of Medical Science, large has announced iPS cells from human (induced pluripotent stem cells), and was produced in the body of the mouse, the hematopoietic stem cells underlying the blood.
The combination of gene therapy with this method was successful in the treatment of blood disorders mice. In the results is expected to lead to new treatments for blood disorders such as leukemia, and was posted to the 14th electronic version of the U.S. gene therapy Journal.
and creating in vitro hematopoietic stem cells from iPS cells is difficult, it is impossible to make hematopoietic stem cells that could be used to treat far. In the body of the animal, the research team focused on nature to create a benign tumor cells and tissues including various blood was mingled the iPS cells. With the cells and proteins necessary for inducing hematopoietic stem cells were transplanted into the waist neighborhood mouse iPS cells in humans. By the practical use, The period of five years appears to be necessary, but please complete the research for practical use.


ヒトのｉＰＳ細胞（人工多能性幹細胞）から、血液のもとになる造血幹細胞を、マウスの体内で作製したと東京大医科学研究所の中内教授らが発表した。
　この方法と遺伝子治療を組み合わせ、血液疾患マウスの治療にも成功した。白血病など血液疾患の新治療法につながると期待される成果で、米遺伝子治療学会誌の電子版に１４日掲載された。
　ｉＰＳ細胞から造血幹細胞を試験管内で作るのは難しく、これまで治療に使えるような造血幹細胞を作ることはできなかった。研究チームは、ｉＰＳ細胞が動物の体内で、血液を含む様々な細胞や組織が混じり合った良性腫瘍を作る性質に着目。ヒトのｉＰＳ細胞を、造血幹細胞を誘導するのに必要なたんぱく質や細胞とともに、マウスの腰周辺に移植した。実用化までには、なお5年ほどの期間が必要なようですが実用化に向けて研究を進めてください。